The world’s most expensive medicine is about to hit the market. A one-time treatment for a devastating infant muscle-wasting disease won approval from the U.S. Food and Drug Administration Friday. Its maker Novartis AG says the gene therapy will cost $2.125 million. The therapy, called Zolgensma, treats an inherited disease called spinal muscular...

Source: Wall Street Journal May 24, 2019 20:48 UTC